Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes [PDF]
Cardiovascular Diabetology, 2013 Background Osteoprotegerin is a member of the tumor necrosis factor-related family and inhibits RANK stimulation of osteoclast formation as a soluble decoy receptor.
Aoki Atsushi +10 more
doaj +2 more sources
Relationship between serum osteoprotegerin and vascular calcifications in hemodialysis patients [PDF]
The Egyptian Heart Journal, 2017 Background: Uremia is a vasculopathic process, and both cardiac calcification and vascular calcification seen from the early stages of chronic kidney disease.
Tarek Z. El Baz +5 more
doaj +2 more sources
Osteoporosis and polymorphisms of osteoprotegerin gene in postmenopausal women – a pilot study [PDF]
Rheumatology, 2016 Objectives: Osteoprotegerin (OPG) has an important role in bone remodeling, and it has been proposed that the OPG gene might be a candidate gene for osteoporosis predisposition.
Selma Cvijetic +5 more
doaj +2 more sources
Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study. [PDF]
PLoS ONE, 2016 Osteoprotegerin, a potent osteoclast activation inhibitor, decreases bone resorption and positively affects bone mineral density. This study examined the association between serum osteoprotegerin levels and bone loss in patients with chronic kidney ...
Chang Seong Kim +10 more
doaj +2 more sources
Association of periodontitis with serum osteoprotegerin level in type 2 diabetic postmenopausal women [PDF]
Journal of the Pakistan Medical AssociationObjective: To evaluate the association of periodontitis with serum osteoprotegerin level according to glycaemic state in postmenopausal type 2 diabetic women.
Dalia Kudier Abbas +1 more
doaj +3 more sources
Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand (RANKL) in the Serum of Healthy Adults [PDF]
The International Journal of Biological Markers, 2002 Aims Osteoprotegerin and the receptor activator of the nuclear factor-κB ligand (RANKL) are decisive factors for maintaining the balance between bone formation and bone resorption.
K. Jung +6 more
doaj +2 more sources
Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. [PDF]
PLoS ONE, 2017 Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis.
Lena Tschiderer +4 more
doaj +1 more source
Effect of fasting versus feeding on the bone metabolic response to running [PDF]
, 2012 Individuals often perform exercise in the fasted state, but the effects on bone metabolism are not currently known. We compared the effect of an overnight fast with feeding a mixed meal on the bone metabolic response to treadmill running. Ten, physically-
Scott, JPR +11 more
core +1 more source
Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss [PDF]
, 2010 Anne-Priscille Trouvin, Vincent GoëbDepartment of Rheumatology, Rouen University Hospital, Rouen, FranceAbstract: Bone remodeling requires a precise balance between resorption and formation.
Vincent Goëb +3 more
core +1 more source
Circulating Osteoprotegerin in Chronic Kidney Disease and All-Cause Mortality [PDF]
, 2021 Joanna Kamińska,1,* Marek Stopiński,1,* Krzysztof Mucha,2,3 Michał Pac,2 Marek Gołębiowski,4 Monika A Niewczas,5,6 Leszek Pączek,2,3 Bartosz Foroncewicz2 1Department of Internal Diseases and Dialysis Unit, West Hospital of Saint John Paul II, Grodzisk ...
Pączek L +7 more
core